A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (257 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: safety tolerabilitytolerability andpharmacodynamicsventilationmechanical
  Phrases that lowered it: mgsingle dosereceiptcomparedimpaired
• Sponsor's past termination rate: 10.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 60 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 11.2% (lowers risk) · Drug's FDA history
• Maximum age: 85 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 33973 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 269 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) NCT03477903 · started 2018 · scored riskier than 68% of active trials terminated
• Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial NCT02784392 · started 2016 · scored riskier than 35% of active trials completed
• Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance NCT01039805 · started 2009 · scored riskier than 20% of active trials completed
• Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study NCT01934192 · started 2014 · scored riskier than 81% of active trials terminated
• Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients NCT03113240 · started 2017 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.